Roquefort Investments PLC

Roquefort Therapeutics plc is a biotechnology company focused on developing medicines for the treatment of cancer. Its portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines: Midkine antibodies, Midkine RNA oligonucleotide therapeutics, Midkine mRNA therapeutics for solid tumors, STAT-6 siRNA therapeutics targeting solid tumors, and MK cell therapy. The company was incorporated in 2020 and is based in London, the United Kingdom.